IFNAR2:JAK1:STAT2 binds JAK1,2 inhibitors

Stable Identifier
R-HSA-9678935
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. JAK1 binds to and is inhibited by several small molecule drugs (Clark et al. 2014, Fridman et al. 2010). Drugs that inhibit these kinases such as baricitinib, tofacitinib, delgocitinib and ruxolitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020).

Literature References
PubMed ID Title Journal Year
24417533 Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

Clark, JD, Flanagan, ME, Telliez, JB

J. Med. Chem. 2014
32511913 Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders

Noji, S, Hara, Y, Miura, T, Yamanaka, H, Maeda, K, Hori, A, Yamamoto, H, Obika, S, Inoue, M, Hase, Y, Orita, T, Doi, S, Adachi, T, Tanimoto, A, Oki, C, Kimoto, Y, Ogawa, Y, Negoro, T, Hashimoto, H, Shiozaki, M

J Med Chem 2020
20130243 Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Quintás-Cardama, A, Vaddi, K, Liu, P, Manshouri, T, Li, J, Scherle, PA, Caulder, E, Wen, X, Li, Y, Waeltz, P, Rupar, M, Burn, T, Lo, Y, Kelley, J, Covington, M, Shepard, S, Rodgers, JD, Haley, P, Kantarjian, H, Fridman, JS, Verstovsek, S

Blood 2010
20363976 Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050

Fridman, JS, Scherle, PA, Collins, R, Burn, TC, Li, Y, Li, J, Covington, MB, Thomas, B, Collier, P, Favata, MF, Wen, X, Shi, J, McGee, R, Haley, PJ, Shepard, S, Rodgers, JD, Yeleswaram, S, Hollis, G, Newton, RC, Metcalf, B, Friedman, SM, Vaddi, K

J. Immunol. 2010
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!